latest development

News & Events

The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and Trademark Office. These molecules can release the enzyme hexokinase-2 (HK2) from the mitochondrial VDAC pores, which triggers an immune response in various types of cancer. This advance strengthens Vidac Pharma's position in the market and demonstrates the potential of its therapies to revolutionize cancer treatment.

For more detailed information, please visit